Novobiocin and rifampicin in combination against methicillin-resistant staphylococcus aureus: An in-vitro comparison with vancomycin plus rifampicin

Thomas J. Walsh, Francois Anger, Beverly A. Tatem, Sharon L. Hansen, Harold C. Standiford

Research output: Contribution to journalArticlepeer-review

Abstract

Novobiocin and rifampicin were evaluated in vitro as a possible new antibiotic combination against methicillin-resistant Staphylococcus aureus. An evaluation of 20 strains of methicillin-resistant Staph. aureus using microdilution checkerboard techniques at 105 cfu/ml showed neither synergy nor antagonism between novobiocin and rifampicin or between vancomycin and rifampicin. Agar surface inoculation of six strains of methicillin-resistant Staph. aureus showed increased synergy with increased inocula (106-109 cfu) for novobiocin plus rifampicin compared to vancomycin plus rifampicin. Time-kill curves showed indifference at 6 h for all combinations, whereas, at 24 and 48 h, they generally showed indifference, occasionally synergy, but never antagonism. The 'synergy' between novobiocin and rifampicin at higher inocula of methicillin-resistant Staph. aureus appears to be due to prevention of emergence of resistant organisms and may have clinical relevance. The combination of novobiocin-rifampicin merits further investigation.

Original languageEnglish (US)
Pages (from-to)75-82
Number of pages8
JournalJournal of Antimicrobial Chemotherapy
Volume17
Issue number1
DOIs
StatePublished - Jan 1986

ASJC Scopus subject areas

  • Pharmacology
  • Microbiology (medical)
  • Infectious Diseases
  • Pharmacology (medical)

Fingerprint

Dive into the research topics of 'Novobiocin and rifampicin in combination against methicillin-resistant staphylococcus aureus: An in-vitro comparison with vancomycin plus rifampicin'. Together they form a unique fingerprint.

Cite this